Tawnie Braaten is a Rheumatology/Immunology physician affiliated with University of Utah. OpenAlex indexes 21 publications with 487 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
University Of Utah Hospital
50 Medical Drive
Salt Lake City, UT 841322155
Telephone
406-480-9387Provider last certified this registry record 28 Oct 2021.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.5%Folate Analog Metabolic Inhibitor19%Methotrexate100%Part D≥42 patientsTNF inhibitor12.7%Enbrel Sureclick45%Humira(Cf) Pen24%Enbrel Mini17%Humira(Cf)14%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
23.7%Corticosteroid15.8%Prednisone100%Part D≥36 patientsAminosalicylate5%Sulfasalazine Dr55%Sulfasalazine45%Part D<11 patients+ 1 more class in this area
Musculoskeletal
12.7%Xanthine oxidase inhibitor6.5%Allopurinol100%Part D≥11 patientsAlkaloid4.2%Colchicine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome
Arthritis Care & Research
2026 - Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study
Journal for ImmunoTherapy of Cancer
2026 - Mortality in <scp>US</scp> Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors
Arthritis Care & Research
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”